1 – 2 of 2
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer : Biomarkers associated with outcomes from OPTIMIZE-1
- Contribution to journal › Article
- 2023
-
Mark
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
- Contribution to journal › Article
